Jazz Pharmaceuticals presents new data on Xywav’s impact at SLEEP 2026

The findings, presented in Dublin, suggest that Xywav’s formulation offers clinical advantages beyond symptom management. Research from the Phase 4 XYLO study indicates that patients switching from high-sodium oxybate to Xywav experienced a reduction in symptoms linked to sodium imbalance, such as edema and nocturia. Furthermore, a retrospective analysis of electronic health records revealed that initiating Xywav correlated with improved lipid profiles, including lower non-HDL cholesterol and triglyceride levels, and a decrease in systolic blood pressure among those previously on high-sodium alternatives.

Beyond cardiovascular health, the data emphasizes the feasibility of individualized dosing. Analysis from the Phase 4 DUET study demonstrated that Xywav allows for flexible, patient-centered regimens, with patients reaching stable doses in roughly six weeks. Real-world insights from the Xywav REMS program, covering over 13,000 patients, reinforce that these tailored approaches are manageable in clinical practice. According to Jessa Alexander, head of neuroscience at Jazz Pharmaceuticals, these results are intended to reshape treatment paradigms by addressing the elevated cardiometabolic risks often faced by patients with these rare sleep disorders.